Ugur Sahin and Özlem Türeci are rapidly becoming “the most celebrated marriage in science since Marie and Pierre Curie discovered radioactivity”, says The Times. The Turkish-German couple behind BioNTech, which developed the break-through Covid-19 vaccine with Pfizer, are just as cosy as their eminent predecessors. They ride everywhere on bikes and spent their honeymoon in white lab coats. When Pfizer’s boss Albert Bourla telephoned to deliver the good news that the vaccine was 90% effective, they celebrated with a cup of tea.
Operation Light Speed
It was the culmination of a long year’s work. Until last year, BioNTech, founded by the couple in 2008 and based in Mainz, was best known for building personalised cancer “vaccines” using messenger ribonucleic acid (mRNA) technology, which uses the cell’s genetic machinery to prompt the body to mobilise against tumours the way it would against a virus. That pioneering work won them the Nobel Prize for Medicine in 2018 and cemented a small personal fortune when BioNTech floated in New York last year. But the couple have always lived modestly.
They were having breakfast in late January when Dr Sahin, 55, mentioned an article he’d read in The Lancet about a strange new disease that appeared to be spreading in Wuhan, China. “When he researched the air links between Wuhan and other cities, he realised that Covid-19 was likely to become a global pandemic.” The couple sprang into action, assigning 600 employees to the hunt for a vaccine in an operation they dubbed Light Speed. As Dr Türeci , 53, puts it, they felt a “moral” imperative to help. Fortunately, their “versatile” mRNA technology proved adaptable. And it was a no-brainer to team up with Pfizer, for whom BioNTech had previously developed flu vaccines.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
News of the Covid-19 vaccine saw BioNTech’s value shoot up to $21.9bn – “more than four times that of German national carrier Lufthansa”, reports The Guardian. They themselves are now worth around £3bn. Since Dr Sahin and Dr Türeci are both children of Turkish gastarbeiter (guestworkers) – an often harried group – their success, as the Berlin newspaper Tagesspiegel noted, was “balm for the soul” of Germans with Turkish roots, after decades of being stereotyped as lowly-educated greengrocers.
A high passion for science
Yet the pair have very different family backgrounds. Dr Sahin is the son of a car factory worker; Dr Türeci’s father was an Istanbul surgeon. She says science has always been her “high passion” – a trait she shares with her husband, who grew up wanting to become a doctor, says The New York Times. They met as students at Saarland University Hospital.
Initially focused on research and teaching, the couple got into business early – founding Ganymed Pharmaceuticals in 2001, says The Times. By the time they came to sell Ganymed for €1.3bn, they’d already established BioNTech as a separate vehicle. The couple have struck up a close friendship with Pfizer’s chief executive Albert Bourla, who is Greek – bonding over “their shared backgrounds as scientists and immigrants”.
According to Dr Sahin, the success of their research proves the benefits of a cosmopolitan exchange of ideas. “In our company we have people from more than 60 countries. In science it does not matter where you are from, what counts is what you can do and what you are willing to do.”
-
8 of the best properties for sale with librariesWe look at eight of the best properties for sale with libraries – from an 1860s baronial mansion in Fife, Scotland, to a Grade II-listed manor in Gloucestershire with a library with flagstone floors and oak columns
-
Stock market turmoil: ‘Should I move money out of investments and into cash instead?’As global stock markets go into turmoil over Trump tariffs, you may be wondering if your money is safe or whether you should sell your shares and move to the so-called safety net of cash accounts
-
Why French far-right leader Marine Le Pen has been banned from running for officeMarine Le Pen, presidential candidate and leader of France's right-wing National Rally party, has been barred from standing by the country's judges.
-
Five years on: what did Covid cost us?We’re still counting the costs of the global coronavirus pandemic – and governments’ responses. What did we learn?
-
Remembering Eddie Jordan: Formula One’s inimitable maverickProfile Eddie Jordan was one of the great characters of motor sport with a zeal for deal-making. His death leaves a hole in the sport that won’t be filled
-
Will Trump force the Fed to lower interest rates?Opinion Markets are ignoring the risk that Donald Trump forces the central bank into reckless interest rate cuts
-
London can lure Brexit-fleeing banks back to UK – but the City must move quicklyOpinion Many banks fled to Paris in the wake of Brexit but are now in full-scale retreat. The City should move quickly to lure them back, says Matthew Lynn
-
Protests erupt in Turkey after the arrest of president Erdogan's rivalTurkey's president has jailed his main political opponent, Ekrem Imamoglu
-
What is the Mar-a-Lago Accord and why is it getting attention from Wall Street?On Wall Street, there is talk that Trump's tariffs aim to make the world’s leaders come crawling to Mar-a-Lago, his Florida residence
-
Palmer Luckey: the billionaire flame of the westProfile Palmer Luckey started Oculus, the virtual-reality headset business, and sold it to Facebook for $2bn. Now he’s set his sights on the arms race.
